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Abstract
Objective and design To investigate the therapeutic effects
of various HDAC inhibitors on the development of chronic
allergic airway disease in mice with airway inflammation,
airway remodeling, and airway hyperresponsiveness.
Subjects Wild-type BALB/C mice (N = 72).
Treatment Tubastatin A HCl [TSA, a selective histone
deacetylase 6 (HDAC6) inhibitor], PCI-34051 (a selective
HDAC8 inhibitor), and givinostat (a broad-spectrum
HDAC inhibitor that inhibits class I and class II HDACs
and several pro-inflammatory cytokines).
Methods Mice were divided into six groups: control,
asthma, dexamethasone (positive control), TSA, PCI-
34051, and givinostat (n = 12 per group). Twenty-four
hours after OVA nebulization, airway hyperresponsive-
ness, inflammation, and remodeling were assessed.
Results The chronic asthma mouse model produced typical
airway inflammation, airway remodeling, and airway
hyperresponsiveness. Administration of PCI-34051 and
dexamethasone reduced the eosinophilic inflammation and
airway hyperresponsiveness in asthma to reduce the airway
remodeling. Treatment with Tubastatin A HCl reduced
airway inflammation and was associated with decreased
IL-4, IL-5 and total inflammatory cell count, as well as
goblet cell metaplasia and subepithelial fibrosis; however,
this outcome was not as effective as that with dexam-
ethasone. TGF-b1 expression in the cytoplasm of airway
epithelium of mice in the Tubastatin A HCl group was
reduced and expression of a-SMA in the airway smooth
muscle was also decreased.
Conclusions The results suggested that treatment with
HDAC inhibitors can reduce airway inflammation, airway
remodeling, and airway hyperresponsiveness in chronic
allergic airway disease in mice.
Keywords Bronchial asthma  Histone deacetylase 
Airway inflammation  Airway hyperresponsiveness
Introduction
Asthma is a chronic respiratory disease having pathological
features such as airway inflammation, airway remodeling
and airway hyperresponsiveness. Long-term repeated
asthma attacks may induce thickening of the bronchial
airway smooth muscle, subepithelial fibrosis, and thicken-
ing of the basement membrane resulting in airway
remodeling and airway collapse [1]. Currently, corticos-
teroids and long-acting b2-agonists are the mainstays of
asthma therapies; however, they do not directly target
airway remodeling (structural changes to the airway wall,
including fibrosis) or airway epithelial susceptibility and
damage [2].
The development of anti-inflammatory drugs that could
complement the currently available therapeutic modalities
is ongoing. Histone deacetylase inhibitors are one such
group of compounds. Developments have been made in the
understanding of histone deacetylase expression in normal
and diseased airways and pulmonary tissue, as well as
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effects of histone deacetylase inhibitors on structural and
inflammatory cells in the lung, including cell proliferation,
differentiation, and apoptosis and senescence. It has been
demonstrated that histone deacetylase inhibitors not only
inhibit tumor cell proliferation, but also have anti-inflam-
matory, anti-fibrotic and anti-angiogenic qualities [1–6],
which can be used for the treatment of airway remodeling
in patients with asthma. Cell experiments and animal
experiments have verified that histone acetylation enzyme
inhibitors can resist cell proliferation, angiogenesis, oxi-
dation, inflammation and fibrosis [3–7].
Selective inhibition of HDAC6 can promote hyper-
acetylation of a-tubulin and HSP90 to inhibit cell motility
and accelerate degradation of HSP90 client proteins, while
it has no significant effect on normal cells [8–12]. This may
be the main reason of HDAC6 inhibitors resisting metas-
tasis and angiogenesis. Histone acetylation enzymes 8
(HDAC8) is expressed in the heart, lungs, liver and kidneys
[7], is an essential factor in the cell survival and prolifer-
ation [8], and it also can regulate differentiation and
contraction of the smooth muscles. Therefore, application
of HDAC8-specific inhibitors may represent a mode of
treatment for asthma [9, 10].
In the current study, the effect of an HDAC6 inhibitor
(Tubastatin A HCl) and an HDAC8 inhibitor (PCI-34051),
on airway inflammation, remodeling, and hyperrespon-




A mouse model of asthma was utilized as previously
described [13, 14]. Briefly, healthy female BALB/C mice
(n = 72) aged 6–8 weeks and weighing 18–22 g were
purchased from the Liaoning Changsheng Biotech Co., Ltd
(license no: SCXK[liao]2010-0001). Animals were housed
independently in a pathogen-free room and provided ad li-
bitum access to water and standard food. Animals were
housed for 1 week prior to experiment onset. Mice were
divided into six treatment groups: normal control, simple
asthma, dexamethasone, Tubastatin A HCl, PCI-34051,
and givinostat. Dexamethasone was purchased from Zhuo
Feng Pharmaceutical Co., Ltd., Zhengzhou, China. All
HDAC inhibitors were purchased from Selleckchem,
Houston, TX, USA. Sensitization was carried out for mice
in the last five groups on the 1st, 8th and 15th day using
ovalbumin (OVA, 20 lg; Sigma, St. Louis, MO, USA) and
aluminum hydroxide gel (2 mg; Sigma). 7 days after the
last sensitization, OVA (20 mg/ml) atomization was per-
formed using an ultrasonic atomizing device (3 ml/min for
30 min, 3 times/week for 8 weeks). Dexamethasone
(2.0 mg/kg) [15], TSA (0.5 mg/kg) [16], PCI-34051
(0.5 mg/kg) and givinostat (0.5 mg/kg) were administered
via intraperitoneal injection 30 min before excitation. In
the normal control group, normal saline was used instead of
OVA. All procedures were approved by the institutional
animal care and use committee (IACUC) at The First
Affiliated Hospital of China Medical University, Republic
of China.
Detection of airway responsiveness
As previously described [17], airway resistance was mea-
sured 24 h following excitation using non-invasive whole
body plethysmography to test pulmonary function (Emka
Technologies, Paris, France). Enhanced pause (Penh) was
recorded 3 min following administration of acetyl-b-
methylcholine chloride at concentrations of 0, 3.125, 6.25,
12.5, 25, and 50 mg/ml (Sigma) to detect airway
resistance.
Detection of cytokines in the bronchoalveolar lavage
fluid using ELISA
Bronchoalveolar lavage fluid was centrifuged at 1200 r/min
for 5 min. Supernatant was collected and stored at -80 C.
Precipitated cells were resuspended in 0.4 ml Hank’s
Balanced Salt Solution (HBSS) and 0.1 ml was taken for
the total cell count. Remaining cells were smeared onto a
clean slide and a differential count was performed after
Wright–Giemsa staining. IL-4, IL-5, IFN-c, and TGF-b1
levels in the bronchoalveolar lavage fluid (BALF) were
measured using ELISA assay kits (CUSABIO, Hubei,
China) per manufacturer’s instructions.
Hematoxylin and eosin staining
Paraffin-embedded tissue sections were dewaxed, stained
with hematoxylin (5–10 min), washed in running tap
water (5 min), differentiated with hydrochloric acid at
room temperature (3 s), washed in running tap water
(30 min), stained with eosin (1–2 min), washed in running
tap water (1 min), dehydrated in a graded alcohol series,
vitrificated in xylene, and mounted in resinous medium.
The inflammatory changes of the lung tissue harvested
from various groups were observed using a light
microscope.
AB-PAS staining
The paraffin-embedded tissue section was dewaxed,
washed in 3 % acetic acid, stained with Alcian blue
(Leagene, Beijing, China), washed in distilled water,
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stained with 0.5 % periodic acid, washed in distilled
water, washed in 70 % alcohol, stained with Schiff’s
reagent (15 min), washed in running tap water (10 min),
stained with hematoxylin, washed in running tap water,
dehydrated using a graded alcohol series, vitrificated in
xylene, and mounted in resinous medium. The prolifera-
tion of goblet cells in the airway was observed using a
light microscope.
Masson’s trichrome staining
The paraffin-embedded tissue section was dewaxed,
stained with Masson’s composite staining solution (Fuzhou
Maixin Bio, Fujian, China) for 5 min, washed in 0.2 %
acetic acid, stained with 5 % tungsten molybdate
(5–10 min), washed in 0.2 % acetic acid twice, stained
with aniline blue (5 min), dehydrated in a graded alcohol
series, vitrificated in xylene, and mounted in resinous
medium. The subepithelial collagen deposition was
observed using a light microscope.
Quantification of various types of cells in BALF
The counting of total cells and cells of different types in
BALF was performed using a light microscope with a
randomly selected visual field (200 cells were counted in
each field). These cells included macrophages (MC),
eosinophils (EOS), neutrophils (N) and lymphocytes (LC).
The percentages of cell types were determined by
counting the number of cells of a specific type per 200
cells.
Detection of a-SMA and TGF-b1 expression using
semi-quantitative immunohistochemistry
Paraffin-embedded tissue sections were de-paraffinized,
hydrated, and washed in PBS three times (5 min each).
Each section was then incubated in 3 % H2O2 at room
temperature and washed in PBS three times (5 min each).
Sections were then treated with 0.01 M citrate buffer (pH
6.0) for antigen retrieval in a microwave oven four times
(6 min for each). Sections were then blocked with 15 %
goat serum at room temperature for 30 min, and then
incubated with primary antibody (1:1000) at 4 C over-
night. The primary antibodies included anti-TGF-b1
antibody (Abcam, Cambridge, UK) anti-alpha smooth
muscle actin antibody (Abcam), while the secondary anti-
body (1:500 at room temperature for 60 min) was
Peroxidase-Conjugated AffiniPure IgG (Zhongshan Golden
Bridge, Beijing, China). After PBS wash, sections were
placed in the DAB color development solution (5–10 min),
rinsed sufficiently in running tap water, counterstained,
dehydrated, vitrificated, and mounted.
Measurement of a-SMA and TGF-b1 expression
in the lung tissue
Protein expression of a-SMA and TGF-b1 was measured
using Western blot assay. Briefly, SDS polyacrylamide gel
electrophoresis (20 lg total protein, pre-stained with 4 ll
marker, treated with 10 % separating gel for 30 min at
80 V, followed by 90 min of electrophoretic separation),
followed by sample incubation with the primary antibodies
[a-SMA (Abcam) and TGF-b1 (Abcam), 1:1000]. A highly
sensitive chemiluminescent detection kit (Super ECL Plus;
PPLYGEN, Beijing, China) was used to measure protein
expression. Sample imaging was carried out using the UVP
imaging system (Upland, CA, USA).
Statistical analysis
Data were presented as mean ± standard deviation (SD)
for each group. Baseline Penh values and other outcomes
were compared using a one-way ANOVA with a post hoc
pair-wise comparison (Bonferroni test). The Penh value for
a given concentration of methacholine (MCh) among
groups was compared using a two-way ANOVA adjusting
baseline Penh value with a post hoc pair-wise comparison
(Bonferroni test). Furthermore, the one-sample test was
performed to compare the expression of western blot with
that of normal control group (setting mean = 1). The dif-
ferences among the remaining five groups were compared
using a one-way ANOVA with a post hoc pair-wise com-
parison (Bonferroni test). All statistical assessments were
two-tailed and considered significantly different as
p\ 0.05. All statistical analyses were carried out using
IBM SPSS statistical software version 22 for Windows
(IBM Corp., Armonk, NY, USA).
Results
The chronic asthma model elicited the expected physio-
logical outcomes. OVA-excited mice in the asthma group
demonstrated sneezing, nasal itching, catching the ear,
urinary and fecal incontinence, and asthma. Furthermore,
the body weight of mice 8 weeks after atomization was
reduced significantly, mental state was poor, the mice
became less active, and their hair lost its shine. These
symptoms were ameliorated in the asthma group, the
dexamethasone group, TSA HCl group, PCI-34051 group,
and givinostat groups. In the normal group, mice did not
experience asthma attacks.
The Penh values for all groups were increased with the
increased concentration of Acetyl-b-methylcholine chlo-
ride (all p\ 0.05; Fig. 1). MCh was associated with
significantly greater Penh values in the asthma group and
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PCI-34051 group compared with the normal control group.
All four treatment groups, including DXM, TSA, PCI-
34051, and givinostat groups, had significantly lower Penh
values compared with the asthma group. The TSA group
had significantly lower Penh values compared with the
DXM group (all p\ 0.05). There were no significant dif-
ferences between TSA, PCI-34051, and givinostat groups
(Fig. 1).
In the asthma group, inflammatory cell (eosinophils and
neutrophils) infiltration was observed surrounding the
peribronchial and perivascular areas and blood vessels, the
airway epithelium was exfoliated, and the airway smooth
muscle and alveolar septum was thickened. Pathological
examination did not show any differences compared with
normal mice. In the dexamethasone and HDAC inhibitor
group the inflammatory cell infiltration around the airway
was reduced compared with the asthma group (Fig. 2).
A higher proportion of PAS positive cells was observed
in the asthma, DXM, TSA, PCI-34051, and givinostat
groups compared with the normal control group (all
p B 0.015; Fig. 3). Moreover, the percentage of PAS
positive cells was decreased significantly in the DXM,
TSA, PCI-34051, and givinostat groups compared with the
asthma group (all p B 0.033). The TSA had a significantly
higher proportion of PAS positive cells compared with the
DXM group (p = 0.029). There were no significant dif-
ferences between TSA, PCI-34051, and givinostat groups
(Fig. 3g).
A higher ratio of collagen deposition around the airway
was observed in the asthma, DXM, TSA, PCI-34051, and
givinostat groups compared with the normal control group
(all p B 0.010; Fig. 4). Moreover, the ratio of collagen
deposition area around the airway was significantly
decreased in DXM, TSA, PCI-34051, and givinostat groups
compared with the asthma group (all p\ 0.001). The TSA
group had a higher ratio of collagen deposition around the
airway compared with the DXM (p = 0.001), PCI-34051
(p = 0.003), and givinostat (p = 0.002) groups, respec-
tively (Fig. 4g).
Total cell numbers were significantly lower in the nor-
mal control group compared with other groups (all
p B 0.020; Fig. 5a). The asthma group had significantly
higher total cell numbers than the DXM, TSA, PCI-34051,
and givinostat groups (all p\ 0.001). The percentage of
macrophages, and eosinophils in the BALF samples were
significantly higher in the TSA group compared with the
DXA, PCI-34051, and givinostat groups (all p\ 0.001;
Fig. 5b).
The asthma group had significantly higher IL-4 levels
compared with the normal control group (p\ 0.001) and
givinostat group (p = 0.012; Fig. 6a). The normal control
group had significantly lower IL-5 levels compared with
the asthma (p\ 0.001) and TSA groups (p = 0.039);
whereas, the asthma group had significantly higher IL-5
levels compared with the DXA, PCI-34051, and givinostat
groups (all p B 0.014; Fig. 6b). The asthma group had
significantly lower IFN-c levels compared with normal
control group (p = 0.009; Fig. 6c). The normal control
group had significantly lower TGF-b1 levels compared
with the asthma (p\ 0.001) and PCI-34051 groups
(p = 0.014; Fig. 6d). The asthma group had significantly
higher TGF-b1 levels compared with the DXM, TSA, PCI-
34051, and givinostat groups (p B 0.019). The levels of IL-
4, IL-5, IFN-c, and TGF-b1 in the BALF samples in TSA,
PCI-34051, and givinostat groups were comparable (all
p[ 0.05).
The asthma group had significantly higher a-SMA
expression (Fig. 7) compared with the normal control
group and other groups (all p\ 0.001). The normal control
group had significantly lower expression of TGF-b1
(Fig. 8) compared with each group, except the givinostat
group (all p B 0.025). The asthma group had significantly
higher TGF-b1 expression compared with DXM, PCI-
34051, and givinostat groups (all p B 0.022). The TSA
group had significantly higher TGF-b1 expression com-
pared with the than givinostat group (all p = 0.049).
Protein expression of a-SMA (Fig. 9) and TGF-b1
(Fig. 10) in mouse lungs varied per administered treat-
ments. The asthma and DXM groups had significantly
higher a-SMA and TGF-b1 protein expression compared
with the normal control group (all p B 0.022). The DXM
group had significantly lower TGF-b1 protein expression
compared with the asthma group (p = 0.039).
Fig. 1 Enhanced pause (Penh values) following stimulation with
acetyl-b-methylcholine chloride (MCh). Data presented as
mean ± SD for each MCh group (n = 8 for each group). Differences
in Penh value change over concentration of MCh among groups were
compared using a two-way ANOVA adjusted for baseline Penh
values. *p\ 0.05, indicated the Penh values was increased along with
the increasing over various concentrations of MCh for each group (all
p values\ 0.001). p\ 0.05, compared with normal control group,
or asthma group
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Discussion
Airway remodeling, as indicated by significant airway
obstruction, smooth muscle hyperplasia, and glandular
hypertrophy, can be observed in patients with chronic
asthma. Smooth muscle hyperplasia, the primary pathology,
aggravates airway hyperresponsiveness, increases airway
thickness, and results in irreversible airflow restriction.
Furthermore, the secretion of cytokines and extracellular
matrix further accelerates airway remodeling [18].
Fig. 2 Representative lung H&E staining. a Normal, no inflamma-
tory cell infiltration around the airway; b asthma, inflammatory cell
infiltration around the airway and blood vessels, the airway smooth
muscle became thick, subepithelial collagen deposition and fibrosis
could be observed; c–f HDAC inhibitor groups and betamethasone
group, inflammatory cell infiltration around the airway and blood
vessels was reduced dramatically
Therapeutic effects of histone deacetylase inhibitors in a murine asthma model 999
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Fig. 3 PAS positive cells in
airway epithelium.
Representative AB-PAS
staining images (a normal
control, b asthma,
c dexamethasone, d TSA,
e PCI-34051, and f givinostat).
The percent of PAS positive
cells (g) are presented as
mean ± SD for each group
(n = 6 for each group). Data
were compared using a one-way
ANOVA with a post hoc pair-
wise comparison, Bonferroni
test. p\ 0.05, significantly
different compared with
*normal control group, asthma
group, or DXM group
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Fig. 4 Ratio of collagen




(a normal control, b asthma,
c dexamethasone, d TSA,
e PCI-34051, and f givinostat).
The percent collagen deposition
area (g) is presented as
mean ± SD for each group
(n = 6 for each group). The
Masson staining positive areas
among groups were compared
using a one-way ANOVA with a
post hoc pair-wise comparison,
Bonferroni test. p\ 0.05,
significantly different compared
with *normal control group,
asthma group, DXM group, or
§TSA group
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The current investigation used a chronic asthma mouse
model to produce airway inflammation, airway remodeling,
and airway hyperresponsiveness. Administration of PCI-
34051 and dexamethasone reduced the eosinophilic
inflammation and airway hyperresponsiveness in asthma to
reduce the airway remodeling. Treatment with Tubastatin
A HCl reduced airway inflammation and was associated
with decreased IL-4, IL-5, and total inflammatory cell
count, as well as goblet cell metaplasia and subepithelial
fibrosis; however, this outcome was not as effective as that
observed with dexamethasone. TGF-b1 expression in the
cytoplasm of airway epithelium of mice in the Tubastatin A
HCl group was reduced and expression of a-SMA in the
airway smooth muscle was also decreased. During our
previous experiments, we proved that application of PCI-
34051, an inhibitor of HDAC8, could relieve the airway
inflammation in asthma and the outcome was as effective
as the steroid.
As the most commonly seen member of the histone
deacetylase family, HDAC6 is mainly distributed in the
cytoplasm and regulates cellular morphology, adhesion, and
migration with a-tubulin, HSP90 and cortical actin as the
substrates [19], while the cellular migration is a prerequisite
of many physiological processes, such as exudation of
leukocytes during inflammation, metastasis of cancer cells,
wound healing [20, 21]. Worth noting, Ito et al. reported that
the expression patterns of HADC1 to HDAC6 in the airway
were similar in between normal subjects and subjects with
asthma, suggesting that HDAC6 may not play a role in the
pathogenesis of asthma [22], possibly as a mediator of LPS-
induced macrophage activation [23].
PCI-34051 is a low molecular-weight hydroxamic acid
and a specific inhibitor of HDAC8 [12, 24]. In the present
study, we found that PCI-34051 could relieve the eosino-
philic inflammation and airway hyperresponsiveness in
asthma to reduce the airway remodeling. After PCI-34051
Fig. 5 Comparison of total cell number (a) and percentages of
various cell types (b) in the BALF sample (n = 6). Data are presented
as mean ± SD for each group (n = 6 for each group). The cell
numbers among groups were compared using a one-way ANOVA
with a post hoc pair-wise comparison, Bonferroni test. p\ 0.05,
significantly different as compared to *normal control group, asthma
group, DXM group, §TSA group, or }PCI-34051 group
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administration, we found that the amount of inflammatory
cells and EOS cells in the BALF decreased, TH2 cell factor
IL-4, IL-5 and TGF-b level reduced significantly, and the
inflammatory cell infiltration around the bronchus
decreased obviously, which suggests that the PCI-34051
treatment can relieve the TH2 immune response.
Improvement of these factors shows that PCI-34051 can
effectively improve the level of inflammation in asthma.
Despite recent studies which demonstrated that broad-
spectrum histone deacetylase inhibitors can relieve airway
inflammation, airway remodeling, and airway hyperre-
sponsiveness associated with asthma [19–22, 25, 26], the
relationship between various members of histone deacety-
lase family and the asthma remains to be fully elucidated.
Banerjee et al. reported that the inhibition of HDAC by
TSA abrogates airway hyperresponsiveness to metha-
choline in both naive and antigen-challenged mice;
however, they also found that TSA did not affect inflam-
mation. The authors concluded that HDAC inhibitors
demonstrate a mechanism of action distinct from that of
anti-inflammatory agents such as steroids, and represent a
promising therapeutic agent for airway disease [3]. Accu-
mulating evidence, including the current investigation, has
indicated beneficial effects in rodent models of allergic
airways disease, the potential use of histone deacetylase
inhibitors in asthma remains controversial given their
mechanisms of action. In short, more specific compounds
may have the potential to ameliorate unwanted side effects,
but will also help further define HDAC inhibitors mecha-
nism of action in asthma [27].
The results suggested that treatment with HDAC inhi-
bitors can reduce airway inflammation, airway remodeling,
and airway hyperresponsiveness in a mouse chronic aller-
gic airway disease model. Occurrence of airway
remodeling in asthma is related to the persistent airway
inflammation and repeated airway epithelium damage/re-
pair. It has been verified that HDAC6 together with
HDAC4 and HDAC8 regulates TGF-b1-mediated a-SMA
expression in the smooth muscle and takes part in the
maintenance of cellular morphology and tissue repair [25].
During the airway remodeling in asthma, Tubastatin A HCl
can inhibit the TGF-b1 expression and further restrict the
airway epithelial-mesenchymal transition to relieve the
airway remodeling in asthma. It was reported that HDAC6
inhibitors might be involved in the biomechanical behav-
iors of the airway smooth muscle cells, such as contraction
of the airway smooth muscle cells, fibrous structure of the
cytoskeleton and tension of the airway smooth muscle cells
[8, 12, 26, 28] to affect the proliferation, migration and
differentiation of airway smooth muscle cells and restrict
the development of airway remodeling. In the present
study, we found that HDAC6 could relieve the airway
inflammation, airway remodeling and airway hyperre-
sponsiveness in asthma. However, the role of HDAC6 in
the treatment of asthma may not be realized by conven-
tional anti-inflammatory effects but achieved by relieving
the epithelial damage/repair and proliferation, differentia-
tion and migration of the airway smooth muscle. Further
studies are planned to help further clarify the proposed
therapeutic pathways.
Fig. 6 The protein levels of IL-4 (a), IL-5 (b), IFN-c (c) and TGF-b1
(d) in the BALF samples. Data were presented as mean ± SD for
each group (n = 6 for each group). Differences of among groups for
each of outcomes were compared using one-way ANOVA with a post
hoc pair-wise comparison, Bonferroni test. p\ 0.05, significantly
different as compared with *normal control group or asthma group
for each of outcomes








(a normal control, b asthma,
c dexamethasone, d TSA,
e PCI-34051, and f givinostat).
Airway smooth muscle area/
airway circumference (g) are
presented as mean ± SD for
each group (n = 6 for each
group). Between group
differences were compared
using a one-way ANOVA with a
post hoc pair-wise comparison,
Bonferroni test. p\ 0.05,
significantly different as
compared with *normal control
group and asthma group








(a normal control, b asthma,
c dexamethasone, d TSA,
e PCI-34051, and f givinostat).
IOD/airway circumference
(g) are presented as mean ± SD
for each group (n = 6 for each
group). Between group
differences were compared
using a one-way ANOVA with a
post hoc pair-wise comparison,
Bonferroni test. p\ 0.05,
significantly different compared
with *normal control group,
asthma group, DXM group,
and §TSA group
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Fig. 9 a-SMA protein expression evidenced by western blot. a Rep-
resentative gel images and, b a-SMA protein expression presented as
mean ± SD for each group. One-sample test was performed the
expression as compared to normal control group (setting mean = 1).
The between-group differences were compared using a one-way
ANOVA with a post hoc pair-wise comparison, Bonferroni test.
p\ 0.05, significantly different as compared with *normal control
group or asthma group
Fig. 10 TGF-b1 protein expression evidenced by western blot.
a Representative gel images and, b TGF-b1 protein expression
presented as mean ± SD for each group. One-sample test was
performed the expression as compared to normal control group
(setting mean = 1). The between-group differences were compared
using a one-way ANOVA with a post hoc pair-wise comparison,
Bonferroni test. p\ 0.05, significantly different as compared with
*normal control group or asthma group
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Study limitations
In this study, a chronic asthma model was employed to
investigate the therapeutic effects of different HDAC
inhibitors on airway inflammation, airway remodeling, and
airway hyper responsiveness. Studies revealed that a
HDAC8 specific inhibitor (PCI-34051) had advantages in
the relief of airway inflammation associated with asthma.
Furthermore, the inhibitory effects of another HDAC
inhibitor (Tubastatin A HCl) on airway inflammation was
slightly inferior to other drugs, but the protective effects of
Tubastatin A HCl on airway hyper responsiveness and
airway remodeling (especially on the expression of TGF-
b1 and a-SMA) were comparable to those of other drugs.
Thus, we speculate that a HDAC8 specific inhibitor may
relieve airway inflammation, airway remodeling, and air-
way hypersensitivity via its anti-inflammatory effect; it
may also inhibit the persistent inflammation in the airway
to relieve the airway remodeling associated with asthma.
An HDAC6 specific inhibitor, however, is more likely to
inhibit the remodeling of structural cells in the airway
thereby inhibiting airway remodeling and airway hyper-
sensitivity. Worth noting, HDAC6 specific inhibitors affect
some biological activities of cells such as exudation,
migration and aggregation of inflammation, suggesting the
anti-inflammatory effect of this drug, but its anti-inflam-
matory effect is not as potent as that of other anti-
inflammatory drugs such as steroids. We therefore specu-
late that HDAC6 specific inhibitors may have limitations in
the treatment of acute inflammation, which may not be
evident in the model of chronic inflammation currently
described. We propose an early acute asthma model would
be better suited for examining the effects of HDAC inhi-
bitors on inflammation observed in asthma.
Future studies will employ an early acute asthma model
to confirm the hypothesis that specific HDAC8 inhibitors
may exert anti-inflammatory effects and the anti-inflam-
matory, anti-remodeling and anti-hypersensitivity effects
are closely related to potent anti-inflammatory activity in
asthma.
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